EUVIMEDOpdag EUVIMED
Open access · CC BY-NC 4.0

Nonlinear Mixed‐Effects Model of Z‐Endoxifen Concentrations in Tamoxifen‐Treated Patients from the CEPAM Cohort

Anna M Mc Laughlin iD, Thomas Helland iD, Fenja Klima iD, Stijn L W Koolen iD, Ron H N van Schaik iD, Ron H J Mathijssen iD, Patrick Neven, Jesse J Swen iD, Henk-Jan Guchelaar iD, Florence Dalenc, Melanie White-Koning iD, Robin Michelet iD and 11 more

Clinical Pharmacology & Therapeutics · 2024-09 · 116 (3) · 690-702

DOI: 10.1002/cpt.3238 ↗

At a glance

Journal article in Clinical Pharmacology & Therapeutics, published online on 2024-03-18. Written by Anna M Mc Laughlin and 22 co-authors. Institution: Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universitaet Berlin, Berlin, Germany. Major MEDLINE topics: Tamoxifen, Cytochrome P-450 CYP2D6, Breast Neoplasms, Antineoplastic Agents, Hormonal. Cited 6 times so far (Crossref); 51 references. The full text is freely available (open access, CC BY-NC 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Tamoxifen is widely used in patients with hormone receptor‐positive breast cancer. The polymorphic enzyme CYP2D6 is primarily responsible for metabolic activation of tamoxifen, resulting in substantial interindividual variability of plasma concentrations of its most important metabolite, Z‐endoxifen. The Z‐endoxifen concentration thresholds below which tamoxifen treatment is less efficacious have been proposed but not validated, and prospective trials of individualized tamoxifen treatment to achieve Z‐endoxifen concentration thresholds are considered infeasible. Therefore, we aim to validate the association between Z‐endoxifen concentration and tamoxifen treatment outcomes, and identify a Z‐endoxifen concentration threshold of tamoxifen efficacy, using pharmacometric modeling and simulation. As a first step, the CYP2D6 Endoxifen Percentage Activity Model (CEPAM) cohort was created by pooling data from 28 clinical studies (> 7,000 patients) with measured endoxifen plasma concentrations. After cleaning, data from 6,083 patients were used to develop a nonlinear mixed‐effect (NLME) model for tamoxifen and Z‐endoxifen pharmacokinetics that includes a conversion factor to allow inclusion of studies that measured total endoxifen but not Z‐endoxifen. The final parent‐metabolite NLME model confirmed the primary role of CYP2D6, and contributions from body weight, CYP2C9 phenotype, and co‐medication with CYP2D6 inhibitors, on Z‐endoxifen pharmacokinetics. Future work will use the model to simulate Z‐endoxifen concentrations in patients receiving single agent tamoxifen treatment within large prospective clinical trials with long‐term survival to identify the Z‐endoxifen concentration threshold below which tamoxifen is less efficacious. Identification of this concentration threshold would allow personalized tamoxifen treatment to improve outcomes in patients with hormone receptor‐positive breast cancer.

Subjects

MeSH terms (MEDLINE)

TamoxifenCytochrome P-450 CYP2D6Breast NeoplasmsAntineoplastic Agents, HormonalNonlinear DynamicsHumansFemaleModels, BiologicalMiddle AgedCohort StudiesTreatment OutcomeComputer SimulationAged

Substances

TamoxifenCytochrome P-450 CYP2D64-hydroxy-N-desmethyltamoxifenAntineoplastic Agents, Hormonal

Authors and institutions

  • Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universitaet Berlin, Berlin, Germany.
  • PharMetrX Graduate Research Training Program, Berlin/Potsdam, Germany.
  • Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, Michigan, USA.
  • Hormone Laboratory, Department of Medical Biochemistry and Pharmacology, Haukeland University Hospital, Bergen, Norway.
  • Department of Clinical Science, University of Bergen, Bergen, Norway.
  • Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.

ORCID profiles: Anna M Mc Laughlin, Thomas Helland, Fenja Klima, Stijn L W Koolen, Ron H N van Schaik, Ron H J Mathijssen, Jesse J Swen, Henk-Jan Guchelaar, Melanie White-Koning, Robin Michelet, Gerd Mikus, Werner Schroth, Hiltrud Brauch, Matthias Schwab, Håvard Søiland, Fabienne Thomas, Charlotte Kloft, Daniel L Hertz

Cite

APA

Mc Laughlin, A. M., Helland, T., Klima, F., Koolen, S. L. W., van Schaik, R. H. N., Mathijssen, R. H. J., Neven, P., Swen, J. J., Guchelaar, H. J., Dalenc, F., White-Koning, M., Michelet, R., Mikus, G., Schroth, W., Mürdter, T., Brauch, H., Schwab, M., Søiland, H., Mellgren, G., …, & CYP2D6 Endoxifen Percentage Activity Model (CEPAM) Consortium (2024). Nonlinear Mixed‐Effects Model of Z‐Endoxifen Concentrations in Tamoxifen‐Treated Patients from the CEPAM Cohort. Clinical Pharmacology & Therapeutics, 116(3), 690-702. https://doi.org/10.1002/cpt.3238

Vancouver

Mc Laughlin AM, Helland T, Klima F, Koolen SLW, van Schaik RHN, Mathijssen RHJ, et al. Nonlinear Mixed‐Effects Model of Z‐Endoxifen Concentrations in Tamoxifen‐Treated Patients from the CEPAM Cohort. Clinical Pharmacology & Therapeutics. 2024;116(3):690-702. doi:10.1002/cpt.3238

BibTeX
@article{McLaughlin2024,
  author = {Mc Laughlin, Anna M and Helland, Thomas and Klima, Fenja and Koolen, Stijn L W and van Schaik, Ron H N and Mathijssen, Ron H J and Neven, Patrick and Swen, Jesse J and Guchelaar, Henk-Jan and Dalenc, Florence and White-Koning, Melanie and Michelet, Robin and Mikus, Gerd and Schroth, Werner and Mürdter, Thomas and Brauch, Hiltrud and Schwab, Matthias and Søiland, Håvard and Mellgren, Gunnar and Thomas, Fabienne and Kloft, Charlotte and Hertz, Daniel L and CYP2D6 Endoxifen Percentage Activity Model (CEPAM) Consortium, CYP2D6 Endoxifen Percentage Activity Model (CEPAM) Consortium},
  title = {Nonlinear Mixed‐Effects Model of Z‐Endoxifen Concentrations in Tamoxifen‐Treated Patients from the CEPAM Cohort},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2024},
  volume = {116},
  number = {3},
  pages = {690--702},
  doi = {10.1002/cpt.3238}
}
Start for free →